Compare · CBLL vs STXS
CBLL vs STXS
Side-by-side comparison of CeriBell Inc. (CBLL) and Stereotaxis Inc. (STXS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CBLL and STXS operate in Biotechnology: Electromedical & Electrotherapeutic Apparatus (Health Care), so they compete in similar markets.
- CBLL is the larger of the two at $1.08B, about 12.0x STXS ($90.2M).
- CBLL has been more active in the news (8 items in the past 4 weeks vs 7 for STXS).
- CBLL has more recent analyst coverage (8 ratings vs 6 for STXS).
- Company
- CeriBell Inc.
- Stereotaxis Inc.
- Price
- -
- -
- Market cap
- $1.08B
- $90.2M
- 1M return
- +6.41%
- -
- 1Y return
- +122.34%
- -
- Industry
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Exchange
- NASDAQ
- AMEX
- IPO
- 2024
- News (4w)
- 8
- 7
- Recent ratings
- 8
- 6
Stereotaxis Inc.
Stereotaxis, Inc. designs, manufactures, and markets robotic magnetic navigation (RMN) systems for use in hospital's interventional surgical suite to improve the treatment of arrhythmias and coronary artery disease in the United States and internationally. Its RMN systems include the Genesis RMN and Niobe systems, which enable physicians to complete complex interventional procedures by providing image-guided delivery of catheters and guidewires through the blood vessels and chambers of the heart to treatment sites. The company also provides Odyssey, a real-time information solution to manage, control, record, and share procedures across networks; and Stereotaxis Imaging Model S X-ray system, a single-plane full-power x-ray system, including c-arm, powered table, motorized boom, and large high-definition monitors for a robotic interventional operating room. In addition, it offers disposables and other accessories, such as QuikCAS automated catheter advancement disposables for the remote advancement of electrophysiology catheters; and CARTO RMT navigation and ablation system, CELSIUS RMT, NAVISTAR RMT, NAVISTAR RMT DS, NAVISTAR RMT THERMOCOOL, and CELSIUS RMT THERMOCOOL irrigated tip diagnostic/ablation steerable tip catheters. Further, the company provides Vdrive, a system that offers navigation and stability for the diagnostic and therapeutic devices designed to improve interventional procedures; and V-Loop, V-Sono, and V-CAS disposable components. Stereotaxis, Inc. markets its products through direct sales force, distributors, and sales agents. The company has a strategic collaboration with Osypka AG to develop a magnetic ablation catheter using Stereotaxis' robotic technology. Stereotaxis, Inc. was founded in 1990 and is based in St. Louis, Missouri.
Latest CBLL
- Director Taylor Joseph Michael sold $277,644 worth of shares (10,200 units at $27.22), decreasing direct ownership by 21% to 38,278 units (SEC Form 4)
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $131,754 worth of shares (4,887 units at $26.96) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by CeriBell Inc.
- CeriBell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Ceribell Reports Third Quarter 2026 Financial Results
- Ceribell Expands Its Point-of-Care Brain Monitoring Platform with Commercial Launch of Delirium Monitoring Solution
- Ceribell to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
- Ceribell to Report Third Quarter 2026 Financial Results on November 3, 2026
- Chief Technology Officer Woo Raymond exercised 4,887 shares at a strike of $3.65 and sold $119,145 worth of shares (4,887 units at $24.38) as part of a pre-agreed trading plan (SEC Form 4)
- Ceribell Receives FDA 510(k) Clearance for Quantitative EEG Trending and Amplitude-Integrated EEG Analysis
Latest STXS
- Stereotaxis Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Results of Operations and Financial Condition, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits
- Stereotaxis Reports 2026 Third Quarter Financial Results & Business Updates
- Stereotaxis Announces Convertible Note Financing of Up To $24 Million
- First-in-Human Coronary Intervention Study Results of Robocath’s Next-Generation Robotic System Highlighted at TCT
- Canon Medical and Stereotaxis Collaborate to Advance Robotic Electrophysiology
- Stereotaxis Announces First Robotic Magnetic Navigation System in Latvia
- Stereotaxis to Report Third Quarter 2026 Financial Results on November 10, 2026
- Stereotaxis Emerging Digital, AI and Automation Capabilities to be Featured at Heart Rhythm Society’s HRX 2026
- University of Szeged Celebrates Strongest First Month of Robotic Cardiology Program
- SEC Form EFFECT filed by Stereotaxis Inc.